Introduction C-ros oncogene 1 (ROS1) translocation is an oncogenic driver-mutation identified in 1% to 2% of non-small-cell lung cancer (NSCLC) cases. Although crizotinib, a tyrosine kinase inhibitor

DataCite Commons2023-12-12 更新70

Real world data of efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.

非小细胞肺癌

药物疗效

Real world data of efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.

NIAID Data Ecosystem50

MOESM3 of Protein signatures of molecular pathways in non-small cell lung carcinoma (NSCLC): comparison of glycoproteomics and global proteomics

蛋白质组学

非小细胞肺癌

Additional file 3. Â Raw data for global peptides from LC-MS.

DataCite Commons2025-04-01 更新90

Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis

非小细胞肺癌

免疫疗法

Purpose This systematic review with network meta-analysis compared the efficacy and safety of currently licensed second-line treatments in patients with late stage non-small cell lung cancer (NSCLC).

NIAID Data Ecosystem50

Additional file 3 of USP21-EGFR-Lyn axis drives NSCLC progression and therapeutic potential of USP21 inhibition

资源简介：

相关数据集